

When you are looking for a biologic treatment for your patients with severe asthma

Think TEZSPIRE®


TEZSPIRE® (tezepelumab injection) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.

TEZSPIRE® is not indicated for relief of acute bronchospasm or status asthmaticus.¹

TEZSPIRE® is available as a **pre-filled pen** or a **pre-filled syringe**¹



Pre-filled pen



Pre-filled syringe

For both devices:¹

- ▶ The recommended dose is 210 mg every 4 weeks
- ▶ The injection is subcutaneous
- ▶ No dose adjustments are required
- ▶ Patients can self-inject at home, after training

Please refer to the Product Monograph for the complete dosing and administration information.

Consult the TEZSPIRE® Product Monograph at www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/tezspire-product-monograph-en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.

Reference:

1. AstraZeneca Canada Inc. TEZSPIRE® Product Monograph. May 10, 2024.

TEZSPIRE® and the logo are trademarks of Amgen Inc. and the Amgen logo is a registered trademark of Amgen Inc., used under license by AstraZeneca Canada Inc. The AstraZeneca logo is a trademark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

© AstraZeneca Canada Inc. 2024. All rights reserved. CA-9523B. Last Updated 09/24